Tibolone cancer data

Researchers from the U.S. Department of Health and Human Service's Agency for Healthcare Research and Quality (AHRQ) performed a comparative effectiveness analysis showing that tamoxifen, raloxifene and tibolone reduced the incidence of invasive breast cancer in midlife and older women, but that each drug carries distinct potential harms. The evaluation of 29 clinical trials showed that the most common side effects of tamoxifen are flushing and other vasomotor symptoms, and vaginal discharge and other vaginal symptoms such as itching or dryness. For raloxifene, side effects include vasomotor symptoms and leg cramps. Side effects for tibolone include vaginal bleeding.

AHRQ also found that tamoxifen increases the risk of endometrial cancer, hysterectomies and cataracts compared with the other two drugs. Tamoxifen and raloxifene increase risk of blood clots, although tamoxifen's risk is greater, while tibolone increases the risk of stroke. ...